Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study

Median overall survival was 16.3 months in the standard cilengitide arm compared to 13.4 months in the control arm.

• The standard cilengitide dose regimen showed a hazard ratio of 0.686, indicating a potential improvement in overall survival.
• The intensive cilengitide arm had a median overall survival of 14.5 months, with a hazard ratio of 0.858, suggesting no significant benefit compared to control.
• Median progression-free survival was 5.6 months in the standard cilengitide arm and 5.9 months in the intensive cilengitide arm, compared to 4.1 months in the control arm.
• Both dosage regimens of cilengitide were well tolerated when combined with standard chemoradiotherapy.
• Inconsistent survival outcomes and a limited sample size hindered definitive conclusions about the clinical efficacy of cilengitide.

AI simplified